San Francisco Reports Significant Declines in STI Rates Following Doxy PEP Rollout
Public health data from San Francisco indicates a substantial decrease in cases of bacterial sexually transmitted infections (STIs), a trend officials credit in large part to the strategic implementation of doxycycline post-exposure prophylaxis, or doxy PEP. The decline is most pronounced among men who have sex with men (MSM) and transgender women, populations that have been the primary focus of local prevention efforts.
What Is Doxy PEP?
Doxy PEP is an STI prevention strategy that involves taking the antibiotic doxycycline after condomless oral or anal sex. The goal is to reduce the risk of acquiring bacterial infections, specifically chlamydia, gonorrhea, and syphilis.
Research has demonstrated significant efficacy for this intervention among specific populations. Studies indicate that for MSM and transgender women who have sex with men, the use of doxy PEP can reduce the risk of chlamydia by 88%, syphilis by 87%, and gonorrhea by 55%. This strategy is not effective for HIV or viral STIs such as herpes or HPV. Clinical research has not found doxy PEP to be effective for cisgender women who engage in penis-in-vagina sex.
Impact on Local Health Trends
San Francisco has been a leader in adopting doxy PEP as a public health tool. Data comparing 2024 to 2025 reveals a meaningful downward trend in infection rates:
- Chlamydia cases dropped by 18%.
- Syphilis cases decreased by 24%.
- Gonorrhea cases fell by 5%.
Dr. Stephanie Cohen, director of STI and HIV prevention and control for the San Francisco Health Department, stated that the drop in STI cases is due in large part to the work that made the rollout of doxy PEP possible. San Francisco Health Officer Dr. Susan Philip emphasized the importance of maintaining this momentum, encouraging the public to prioritize sexual health through regular testing.
Clinical Guidelines and Considerations
The Centers for Disease Control and Prevention (CDC) currently recommends that healthcare providers discuss doxy PEP with MSM and transgender women who have sex with men. According to CDC guidelines, individuals within these communities who have been diagnosed with an STI in the past year are considered ideal candidates for this prophylaxis.
Addressing Antibiotic Resistance
As the use of doxy PEP expands, some experts have raised concerns regarding antibiotic resistance. Bacteria responsible for STIs, particularly gonorrhea, have demonstrated an increasing ability to resist various classes of antibiotics. There is ongoing discussion in the medical community about whether widespread use of doxycycline could accelerate bacterial evolution, potentially rendering the treatment less effective over time.
While researchers continue to monitor these developments, the current consensus among public health experts supports the continued use of doxy PEP. The data observed in San Francisco suggests that, at least in the short term, the strategy is having a measurable and positive impact on controlling the spread of bacterial STIs.
Key Takeaways
- Targeted Prevention: Doxy PEP is currently recommended for MSM and transgender women who have sex with men and have a history of recent bacterial STIs.
- Proven Efficacy: The strategy shows high efficacy in reducing rates of chlamydia, syphilis, and gonorrhea in the studied populations.
- Limitations: Doxy PEP does not prevent HIV or viral STIs and has not shown effectiveness in clinical studies involving cisgender women.
- Ongoing Monitoring: While the public health results are encouraging, clinicians remain vigilant regarding the potential for antibiotic resistance.
Worth a look